Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | LOX | P28300 | 9/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | NR1D1 | P20393 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1467277 | 0.98 | — | — | |
| SCHEMBL30758544 | 0.86 | LTA4H (0.50) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| Acetic Acid SCHEMBL4574444 | 0.85 | LOX (0.39) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| Iodide SCHEMBL30758524 | 0.84 | LTA4H (0.49) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| Hydrochloric Acid SCHEMBL6685145 | 0.83 | LOXL2 (0.33) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| Hydrochloric Acid SCHEMBL6684401 | 0.83 | CYP2E1 (0.30) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| Hydrochloric Acid SCHEMBL6689615 | 0.83 | TRPA1 (0.34) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL22788280 | 0.80 | LOX (0.37) | CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL22774992 | 0.76 | — | — | |
| SCHEMBL128303 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| EP-4069678-A1 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115103709-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115052862-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| WO-2021113690-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-1228783-A | Novel thrombin inhibitors | BASF AG (DE) | 1999-09-15 | — | — | CN | disclosed |
| WO-1999037611-A1 | HETEROCYCLIC AMIDINES AS CALLICREIN PROTEASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-29 | — | — | WO | disclosed |
| US-5914319-A | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1999-06-22 | — | — | US | disclosed |
| US-5726159-A | PEPTIDE THROMBIN INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1998006741-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | disclosed |
| US-5710130-A | HETEROCYCLIC SYNTHETIC PEPTIDES | ELI LILLY AND COMPANY (US) | 1998-01-20 | — | — | US | disclosed |
| US-5707966-A | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| US-5705487-A | PEPTIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0672658-A1 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995023609-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | MAOA 3092/4885CYP2E1 4846/4885CYP2A6 4656/4885 |
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | MAOA 3092/4885CYP2E1 4846/4885CYP2A6 4656/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | MAOA 3092/4885CYP2E1 4846/4885CYP2A6 4656/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | MAOA 3092/4885CYP2E1 4846/4885CYP2A6 4656/4885 |
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | MAOA 3092/4885CYP2E1 4846/4885CYP2A6 4656/4885 |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | MAOA 3092/4885CYP2E1 4846/4885CYP2A6 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.